干细胞治疗市场规模、份额和成长分析：按类型、治疗应用、细胞来源、地区 - 产业预测，2024-2031

2022年全球干细胞治疗市场规模将达到110亿美元，预测期内（2024-2031年）复合年增长率为11.2%，从2023年的122.3亿美元增加到2031年的286亿美元。美元。

全球干细胞治疗市场的重点是利用干细胞治疗各种疾病和病症。干细胞是一种独特的细胞，可以分化成各种类型的细胞并进行自我复製，有潜力为再生医学带来突破性进展。这种治疗方法旨在修復或替换受损的组织和器官，用于治疗心血管疾病、神经退化性疾病、整形外科损伤、自体免疫疾病和某些癌症等治疗方法。 。市场成长的主要驱动力是慢性病和老龄化相关疾病盛行率的上升。然而，干细胞疗法面临挑战，包括高成本、标准化法规的需求以及生产中的扩充性和成本效益问题。儘管存在这些障碍，该市场仍具有巨大潜力，越来越多的临床试验和研究探索干细胞疗法的潜力。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价格分析
• 价值链分析
• 供应链分析
• 案例研究分析
• 市场生态系统
• 客户和购买标准分析
• 专利分析
• 监管环境
• PESTEL分析
• 创新矩阵
• 重点投资分析
• 关键成功因素
• 市场魅力指数
• 竞争程度

干细胞治疗市场：依细胞来源分类

• 市场概况
• 脂肪组织来源的间质干细胞
• 骨髓间质间质干细胞
• 胎盘/脐带间质间质干细胞
• 其他的

干细胞治疗市场：依类型

• 市场概况
• 同种异体干细胞疗法
• 自体干细胞治疗

干细胞治疗市场：依治疗应用分类

• 市场概况
• 肌肉骨骼疾病
• 伤口/手术
• 再生医学
• 药物发现与开发
• 发炎疾病/自体免疫疾病
• 心血管疾病
• 神经系统疾病
• 其他的

干细胞治疗市场规模：依地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 英国
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Novartis AG（Switzerland）
• Pfizer Inc.（US）
• Mesoblast Limited（Australia）
• Celgene Corporation（a subsidiary of Bristol Myers Squibb）（US）
• TiGenix NV（a subsidiary of Takeda Pharmaceutical Company Limited）（Belgium）
• Gamida Cell Ltd.（Israel）
• Vericel Corporation（US）
• Medipost Co., Ltd.（South Korea）
• Astellas Pharma Inc.（Japan）
• Osiris Therapeutics, Inc.（US）
• NuVasive, Inc.（US）
• Cynata Therapeutics Limited（Australia）
• Cellular Dynamics International（a subsidiary of FUJIFILM Holdings Corporation）（US）
• Lonza Group Ltd.（Switzerland）
• Caladrius Biosciences, Inc.（US）
• Athersys, Inc.（US）
• Cytori Therapeutics, Inc.（US）
• Holostem Terapie Avanzate Srl（Italy）
• Pluristem Therapeutics Inc.（Israel）
• BioTime, Inc.（US）
• Smith+Nephew（UK）
• JCR Pharmaceuticals Co., Ltd.（Japan）
• Anterogen Co., Ltd.（South Korea）
• Corestem, Inc.（South Korea）
• Pharmicell Co., Ltd（South Korea）
• Nuvasive, Inc.（US）
• RTI Surgical（US）
• Allosource（US）
• Holostem Terapie Avanzate Srl（Italy）
• Orthofix Medical Inc.（US）
• Stempeutics Research Pvt Ltd.（India）
• Regrow Biosciences Pvt Ltd.（India）
• Mesoblast Ltd.（Australia）
• Biorestorative Therapies, Inc.（US）
• Brainstorm Cell Limited（Israel）
• Viacyte, Inc.（US）
• Kangstem Biotech Co., Ltd.（South Korea）
• Hope Biosciences（US）
• Cellular Biomedicine Group（US）
• Personalized Stem Cells（US）

Global stem cell therapy market size was valued at USD 11 billion in 2022 and is poised to grow from USD 12.23 billion in 2023 to USD 28.60 billion by 2031, at a CAGR of 11.2% during the forecast period (2024-2031).

The global stem cell therapy market focuses on utilizing stem cells to treat a range of diseases and conditions. Stem cells are unique because they can differentiate into various cell types and self-renew, offering potential breakthroughs in regenerative medicine. This therapy aims to repair or replace damaged tissues and organs, addressing conditions like cardiovascular diseases, neurodegenerative disorders, orthopedic injuries, autoimmune diseases, and certain cancers where current treatments are limited. Key drivers for market growth include the rising prevalence of chronic and age-related diseases. However, the market faces challenges, such as the high costs of stem cell therapies, the need for standardized regulations, and issues related to scalability and cost-effectiveness in production. Despite these obstacles, the market holds substantial potential, with a growing pipeline of clinical trials and research studies exploring the possibilities of stem cell therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Stem Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Stem Cell Therapy Market Segmental Analysis

Global stem cell therapy market is segmented on the cell source, type, therapeutic application and region. Based on cell source, the market is segmented into Adipose Tissue-derived Mesenchymal Stem Cells, Bone Marrow-derived Mesenchymal Stem Cells, Placenta/Umbilical Cord-derived Mesenchymal Stem Cells, Other. Based on type, the market is segmented into allogeneic stem cell therapy, and autologous stem cell therapy. Based on therapeutic application, the market is segmented into Musculoskeletal Disorders, Wounds & Surgeries, Regenerative Medicine, Drug Discovery and Development, Inflammatory & Autoimmune Diseases, Cardiovascular Diseases, Neurological Disorders, and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Stem Cell Therapy Market

The growing prevalence of chronic diseases, including cardiovascular disorders, neurodegenerative conditions, and orthopedic injuries, is a major factor driving the stem cell therapy market. Stem cell therapies hold the promise of regenerating damaged tissues and organs, offering innovative treatment options for conditions that currently have limited or no effective treatments. This potential for tissue repair and regeneration makes stem cell therapies an appealing solution for addressing a range of serious health issues.

Restraints in the Stem Cell Therapy Market

The substantial cost of stem cell therapies is a major obstacle to their widespread adoption. The high price is driven by factors such as extensive research and development, complex manufacturing processes, and stringent regulatory requirements. These costs can restrict access to stem cell treatments, particularly for patients in lower-income areas, thereby limiting the broader availability and implementation of these potentially transformative therapies.

Market Trends of the Stem Cell Therapy Market

Allogeneic stem cell therapies, which utilize cells from donors, are becoming increasingly popular in the market. This method provides several benefits, including standardized and readily accessible cell sources, lower manufacturing costs, and the potential for off-the-shelf treatments. As a result, many companies are now concentrating on advancing allogeneic cell therapy products, leading to a growing number of clinical trials and product development initiatives in this field.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Case Study Analysis
• Ecosystem of the Market
• Customer & Buying Criteria Analysis
• Patent Analysis
• Regulatory Landscape
• PESTEL Analysis
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Stem Cell Therapy Market by Cell Source

• Market Overview
• Adipose Tissue-derived Mesenchymal Stem Cells
• Bone Marrow-derived Mesenchymal Stem Cells
• Placenta/Umbilical Cord-derived Mesenchymal Stem Cells
• Other

Stem Cell Therapy Market by Type

• Market Overview
• Allogeneic Stem Cell Therapy
• Autologous Stem Cell Therapy

Stem Cell Therapy Market by Therapeutic Application

• Market Overview
• Musculoskeletal Disorders
• Wounds & Surgeries
• Regenerative Medicine
• Drug Discovery and Development
• Inflammatory & Autoimmune Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Other

Stem Cell Therapy Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • Italy
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesoblast Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (a subsidiary of Bristol Myers Squibb) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited) (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gamida Cell Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vericel Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medipost Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osiris Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NuVasive, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynata Therapeutics Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellular Dynamics International (a subsidiary of FUJIFILM Holdings Corporation) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caladrius Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athersys, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytori Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Holostem Terapie Avanzate S.r.l. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pluristem Therapeutics Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioTime, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith+Nephew (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anterogen Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corestem, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmicell Co., Ltd (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nuvasive, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RTI Surgical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allosource (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Holostem Terapie Avanzate Srl (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orthofix Medical Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stempeutics Research Pvt Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regrow Biosciences Pvt Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesoblast Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biorestorative Therapies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Brainstorm Cell Limited (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viacyte, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kangstem Biotech Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hope Biosciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellular Biomedicine Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Personalized Stem Cells (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments